The President and Chief Executive Officer of Artiva Biotherapeutics, Inc. is Dr. Fred Aslan, M.D. He has guided the company since early 2021, bringing extensive venture capital and operational biotechnology leadership to oversee the clinical advancement of its allogeneic NK cell programs through global clinical trials and strategic financing milestones.